- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASH 2023: PERSEUS Trial Overview
Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.
EP: 1.Unmet Needs and Treatment Approaches in Newly Diagnosed Multiple Myeloma
EP: 2.ASH 2023: PERSEUS Trial Overview
EP: 3.Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients
EP: 4.ASH 2023: Analyzing IsKia Trial
EP: 5.Examining Data from MonumenTAL-2 Study
EP: 6.Optimizing Bispecific Use in Multiple Myeloma Treatment
EP: 7.Navigating Impact of RRMM Treatment on Patient Quality of Life
EP: 8.Key RRMM-Related Takeaways from ASH 2023
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
The PERSEUS trial compared bortezomib, lenalidomide, and dexamethasone (VRd) to lenalidomide, bortezomib, and dexamethasone plus daratumumab (D-VRd) in over 700 newly diagnosed, transplant-eligible multiple myeloma patients. After induction, stem cell transplant, and consolidation with the same regimens, patients in the VRd arm received lenalidomide maintenance while patients in the D-VRd armreceived daratumumab plus lenalidomide. Importantly, minimal residual disease (MRD) testing occurred, allowing therapy discontinuation in sustained MRD-negative complete responders after 2 years.
At 4 years, progression-free survival was 84.3% with D-VRd vs 67.7% with VRd (HR, 0.42), a statistically significant difference. Response rates including complete response and MRD negativity also favored D-VRd. Given the strength of these phase 3 results, D-VRd should be considered for initial induction for transplant-eligible myeloma. Adding daratumumab improves outcomes, including in the maintenance setting, while generic availability makes this affordable globally.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More
Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score
April 8th 2025The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) stratified by their Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score.
Read More
Guselkumab Shows Sustained Efficacy in Phase 3b APEX Study for Active PsA
April 8th 2025Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting structural damage in patients with active psoriatic arthritis (PsA).
Read More
